Prognostic Value of Pre- and Post-Treatment PET-CT Metrics After Definitive Chemoradiation for Anal Canal Cancer
Authors:
- Raksha M. NarasimhanRNRaksha M. Narasimhan
- Yuntao WangYWYuntao Wang
- Justin T. DreyerJDJustin T. Dreyer
- Aren S. SainiASAren S. Saini
- Armando VeraAVArmando Vera
- Yunze YangYYYunze Yang
- Ifeanyichukwu C. OgobuiroIOIfeanyichukwu C. Ogobuiro
- Russ KukerRKRuss Kuker
- Kyle R. PadgettKPKyle R. Padgett
- Aaron H. WolfsonAWAaron H. Wolfson
Open Access
- 18 November 2026
- journal article
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 57 (1)
Abstract
Purpose: Although post-treatment FDG-PET/CT is frequently obtained following definitive chemoradiation (CRT) for locally advanced anal canal cancer (LAACC), its prognostic utility remains uncertain. We hypothesized that quantitative PET/CT metrics would be associated with overall survival (OS) and that pre-treatment metabolic parameters would provide greater prognostic information than post-treatment metabolic response. Methods: We conducted a retrospective cohort study of patients with LAACC who underwent definitive CRT and both pre-treatment and post-treatment fluorodeoxyglucose (FDG) PET/CT. Quantitative PET metrics were extracted, including mean SUL, total lesion glycolysis (TLG), metabolic tumor volume (MTV), maximum SUL, and peak SUL. OS was estimated using the Kaplan-Meier method. Associations between PET-derived variables and OS were evaluated using univariable Cox proportional hazards regression, with optimal cutoffs identified using maximally selected rank statistics (MaxStat). Results: Forty-five patients were included (median age 57.7 years), with post-treatment PET/CT performed at a median of 4.4 months following CRT. Lean body mass (HR 3.10, 95% CI 1.01–9.50; p = 0.049) and pre-treatment primary tumor mean SUL (HR 4.93, 95% CI 1.40–17.37; p = 0.013), size (HR 4.01, 95% CI 1.22–13.17; p = 0.022), TLG (HR 3.68, 95% CI 1.11–12.14; p = 0.033), and peak SUL (HR 3.31, 95% CI 1.02–10.72; p = 0.046) were associated with OS in exploratory univariable analyses. Post-treatment, higher weight (HR 4.94, 95% CI 1.06–22.96; p=0.041; cutoff 60.42 kg; N=45) and lean body mass (HR 4.82, 95% CI 1.06–21.90; p=0.042; cutoff 44.50 kg; N=44) were associated with worse OS. No post-treatment PET-derived metabolic parameters met the nominal threshold for statistical significance. Among patients with higher baseline metabolic activity, greater reduction in mean SUL following CRT demonstrated a nonsignificant trend toward improved OS. Conclusion: Pre-treatment FDG-PET/CT metabolic parameters demonstrated stronger associations with OS than post-treatment metabolic parameters in this exploratory cohort. Baseline tumor metabolic activity may provide useful prognostic information in patients with LAACC, warranting validation in larger prospective studies.This publication has 25 references indexed in Scilit:
- ACR Appropriateness Criteria® Staging and Follow-up of Anal CancerJournal of the American College of Radiology, 2025
- Accuracy and Clinical Impact of Persistent Disease Diagnosed on Diffusion-Weighted Imaging and Accuracy of Pelvic Nodal Assessment on Magnetic Resonance Imaging for Squamous Cell Carcinoma of the Anus in the 6-Month Interval Post ChemoradiotherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2024
- Training and external validation of pre-treatment FDG PET-CT-based models for outcome prediction in anal squamous cell carcinomaEuropean Radiology, 2023
- Prognostic impact of post-treatment FDG PET/CT in anal canal cancer: A prospective studyRadiotherapy and Oncology, 2023
- The Predictive Value of Post-Treatment PET-CT Imaging for Patients With Curable Anal Canal CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2021
- A prospective, multi-centre trial of multi-parametric MRI as a biomarker in anal carcinomaRadiotherapy and Oncology, 2020
- Posttreatment FDG-PET-CT response is predictive of tumor progression and survival in anal carcinomaPractical Radiation Oncology, 2016
- Metabolic tumour volume of anal carcinoma on 18FDG PET/CT before combined radiochemotherapy is the only independant determinant of recurrence free survivalEuropean Journal of Radiology, 2016
- The assessment of local response using magnetic resonance imaging at 3- and 6-month post chemoradiotherapy in patients with anal cancerEuropean Radiology, 2016
- RTOG 0529: A Phase 2 Evaluation of Dose-Painted Intensity Modulated Radiation Therapy in Combination With 5-Fluorouracil and Mitomycin-C for the Reduction of Acute Morbidity in Carcinoma of the Anal CanalInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2013